Adian Valdez

Dec 6, 2024 | cell.com | Kaitlin R Sprouse |Marcos Miranda |Nicholas J. Catanzaro |Amin Addetia |Cameron Stewart |Jack Brown | +19 more

KeywordsMERS-CoVEMPEMnanoparticlevaccineRBDNTDspikeResearch topic(s)CP: ImmunologyIntroductionThe recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the human and economic toll that can accompany the spillover and spread of a zoonotic disease in humans. Although the success of vaccine development efforts in response to the pandemic were a triumph of modern vaccinology, SARS-CoV-2 remains the only coronavirus for which licensed vaccines are available.

Oct 7, 2024 | nature.com | Marcos Miranda |Chengbo Chen |Kaitlin R Sprouse |Adian Valdez

AbstractWe previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovioneTM.